Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review - Wikidata - awgldk - TriplyDB

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review

http://www.wikidata.org/entity/Q26770716

about

Patterns of care and survival outcomes examining radiation therapy for advanced Hodgkin lymphoma.Hodgkin's Lymphoma - evaluation of patients submitted to Autologous transplantation of hematopoietic cells in the Hematology Service of the Hospital Walter Cantídio - Fortaleza, Brazil.New agents in relapsed/refractory Hodgkin's lymphoma.High frequency of primary refractory disease and low progression-free survival rate of Hodgkin's lymphoma: a decade of experience in a Latin American center.High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma.

P2860

Q39658515-6703956E-8FC0-4CB5-BBDA-DBBD4D0803DF Q40422018-57444175-F0C5-4FD7-A8BA-4B330A442047 Q41500227-1049DA02-4A56-4E38-BA82-01F133BF6273 Q46879226-B0AF61D4-658E-4BD2-ACD3-7D775635C987 Q52560940-E7DE0F72-F683-4E27-B770-E65FC0CB218A

P2860

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review

http://www.wikidata.org/entity/Q26770716

description

2015 nî lūn-bûn

@nan

2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review

@ast

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review

@en

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review

@nl

type

label

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review

@ast

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review

@en

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review

@nl

prefLabel

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review

@ast

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review

@en

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review

@nl

P1433

Q26770716-A793ECA6-B34F-4AFF-8A46-FD1EC4E020AC

P1476

Q26770716-106CD2A2-08B5-4A36-A02A-87CF892E7221

P2093

Q26770716-1F666E50-25A4-47F2-A183-F049C526329A

Q26770716-31DE6C4A-E6BC-4EB8-BDC2-56DAF0E8038A

Q26770716-AE04AC31-1F52-4C15-AE3D-BD773D8F7D16

Q26770716-B7144787-DDFA-48E1-BC0F-D8AC79C730C5

P275

Q26770716-D59CBB6B-9249-404E-AC36-E68BA26030FB

P2860

Q26770716-0347C11D-171F-4D9C-9772-BB280FA16D03

Q26770716-03514FAD-1B91-423D-A1DD-E7F6DC86C3D9

Q26770716-07BC90B6-6FE6-41CF-BF08-F5B65B9EDF63

Q26770716-08860AE3-D097-4AB9-81CD-CFD58095FDA6

Q26770716-0AFA7293-F408-47CD-AA9B-897ACBD3D1BD

Q26770716-0FEEF9C5-7F70-4D3E-95B8-2A6FB716CB20

Q26770716-131103C8-386E-416C-8136-20F1BEA2FD75

Q26770716-25292FAC-4120-4EA7-9197-C2DDAEE92D0C

Q26770716-26A298C0-07A2-4843-BFB4-90F2B1BFBE82

Q26770716-2C93B034-498E-4FC5-B105-04DD863B7FEC

P304

Q26770716-78A12789-8BAF-45E6-AD1B-1F724AFDFD60

P31

Q26770716-ACF06FF7-ADEF-4C4E-A1E8-E7893D7F1CB4

Q26770716-EC05A5C7-1CE8-4986-9FB5-6A97EEBBCB1C

P356

Q26770716-D28C4060-6315-46DC-8F7E-7BDDC1F8E292

P407

Q26770716-512D7471-151B-4D4B-9469-305FC96C762E

P478

Q26770716-4E64BA6D-1C3A-4EA9-9532-B8484FA5CD4A

P50

Q26770716-10AC1663-4C46-4505-9E25-CF138D362F97

Q26770716-60347386-94CF-4304-A54F-B4B1C62C47AD

P5008

Q26770716-A29921A2-0A9A-40C7-BDC7-B8FAC3022023

P577

Q26770716-BDF711FD-6255-46EF-917E-6EE12814A346

P5875

Q26770716-E45C69ED-DC06-449C-9A9C-FD1536023E43

P698

Q26770716-2F72F8EC-34D1-4433-BDDC-EE315F1636E9

P921

Q26770716-41B879F8-5D41-46BA-8C1D-E5D0C493A10E

Q26770716-68C79726-8397-4460-A012-B4A249DF43E5

Q26770716-706E8BDB-573C-4F62-A995-9B07A5EFD257

Q26770716-AB13F1A5-F0E0-42B7-B1DD-CBE5B9EE8D88

Q26770716-AD49CD1A-AC29-442D-AA17-2907AD85ED7B

P932

Q26770716-AC38E380-E86B-4F3E-A195-63E3CB50441B

P356

P1433

Journal of Immunology Research

P1476

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review

@en

P2093

Fortunato Morabito

http://www.w3.org/2001/XMLSchema#string

Giuseppe Irrera

http://www.w3.org/2001/XMLSchema#string

Massimo Gentile

http://www.w3.org/2001/XMLSchema#string

Roberta Fedele

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Immune Checkpoint Blockade in Cancer Therapy

Advances in the treatment of relapsed or refractory Hodgkin's lymphoma

The blockade of immune checkpoints in cancer immunotherapy

Cancer statistics, 2014

Immune checkpoint blockade: a common denominator approach to cancer therapy

The EBMT activity survey: 1990-2010

Tumor Immunotherapy Directed at PD-1

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.

P304

968212

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2015/968212

http://www.w3.org/2001/XMLSchema#string

P407

P478

2015

http://www.w3.org/2001/XMLSchema#string

P50

Anna Grazia Recchia

Massimo Martino

P5008

P577

2015-12-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

290514753

http://www.w3.org/2001/XMLSchema#string

P698

26788526

http://www.w3.org/2001/XMLSchema#string

P921

Hodgkin's lymphoma

mechanism of action

monoclonal antibody

P932

4695673

http://www.w3.org/2001/XMLSchema#string